Undiarrhea

Quick links to important sections

Undiarrhea

Method of action: Antidiarrheal, Obstructive

Treatment option: Irritable Bowel Syndrome

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Undiarrhea

Property Description
Active ingredient Loperamide hydrochloride
Form Oral (tablets, capsules, solution)
Pharmacological class Peripheral μ-opioid receptor agonist
Common use Symptomatic relief of acute bowel disturbance
Origin Synthetic

What Type of Medicine is Undiarrhea?

Undiarrhea is a type of gastrointestinal agent primarily classified as an antidiarrheal medication, used to manage acute disturbances in bowel function. This medication's action is defined by its active ingredient, Loperamide hydrochloride, which is officially categorized as a peripheral μ-opioid receptor agonist. This pharmacological classification indicates that the compound interacts specifically with opioid receptors located in the wall of the gastrointestinal tract, a mechanism clinically recognized for its efficacy in controlling motility. This distinctive peripheral action ensures the medication is focused on the gut, avoiding the central nervous system effects associated with other opioid compounds at standard therapeutic doses.


Composition, Forms, and Origin of Loperamide

Loperamide is a compound of synthetic origin, manufactured through chemical processes, and is generally offered as a single active ingredient product. The chemical structure of Loperamide is a derivative of phenylpiperidine, confirming its synthetic production. The medication is available for the oral route of administration in various common dosage forms, including traditional tablets, hard gelatin capsules, caplets, and, in some preparations, an oral solution. Loperamide is globally recognized as the active substance in several formulations marketed for diverse patient groups, demonstrating its broad acceptance as a non-prescription option for managing common, non-specific diarrhea.


What is the General Purpose of Undiarrhea?

The primary purpose of Undiarrhea is to provide symptomatic relief from the urgency and inconvenience of loose, frequent bowel movements. It achieves this by functioning as an anti-motility agent, which means it slows down the natural, rapid muscle contractions (propulsive peristalsis) of the intestine. This slowing action is clinically beneficial because it increases the transit time of contents through the gut, allowing the intestinal wall a greater opportunity to reabsorb necessary water and electrolytes. Consequently, this action helps prevent excessive fluid and electrolyte loss and contributes to the formation of firmer stools, restoring a more comfortable and regular intestinal function, such as during a temporary disturbance like traveler's diarrhea.

Regulatory References

  1. Loperamide drug information

What side effects are possible with Undiarrhea?

Possible Side Effects and Safety Information for Undiarrhea

This information details the officially documented adverse reactions and safety restrictions for Undiarrhea, as reported in regulatory agency documents. The data is structured by the frequency of occurrence and the body system affected.

Frequency-Classified Adverse Reactions

The following side effects are categorized based on their incidence:

Classification Examples of Reactions
Very Common (ge 1/10) Headache, Dry Mouth
Common (ge 1/100 to < 1/10) Nausea, Dizziness, Abdominal Pain
Uncommon (ge 1/1,000 to < 1/100) Rash, Dyspepsia
Rare (ge 1/10,000 to < 1/1,000) Angioedema
Frequency Not Known Severe cutaneous reactions (e.g., Stevens-Johnson Syndrome)

Side effects are classified across several System-Organ Classes, including Nervous System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions (SARs) documented in regulatory sources include Angioedema, Anaphylactic reaction, and severe cutaneous reactions (e.g., SJS). These reactions are rare but considered clinically significant.

Safety-Related Restrictions: Undiarrhea is contraindicated in patients with a known hypersensitivity to the drug or any component, and in those with severe hepatic impairment. Use is not recommended for pediatric patients under 12 years of age as safety and efficacy have not been established in this group. Dosage adjustment is required for patients with moderate to severe renal impairment.

Safety Patterns: Regulatory data indicates that common side effects, specifically headache and nausea, were observed to be more frequent during the first 7 days of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation on Loperamide hydrochloride overdose describes severe potential manifestations impacting the central nervous system (CNS), cardiovascular system, and gastrointestinal tract. Overdose may result in CNS depression, characterized by stupor, depressed consciousness, somnolence, and respiratory depression.

Documented Severe Outcomes

Serious, life-threatening complications are documented, including cardiac events such as QT interval prolongation, Torsade de Pointes, and cardiac arrest. Other severe outcomes include paralytic ileus and toxic megacolon.

Required Emergency Actions

Regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted immediately if the affected person exhibits signs of severe toxicity, including unresponsiveness, trouble breathing, or a rapid, irregular heartbeat (ventricular arrhythmias).

Management and Monitoring

Treatment is supportive and symptomatic. The label states that Naloxone can be administered as an antidote to reverse the CNS and respiratory depression symptoms. Continuous ECG monitoring and hospital observation for at least 48 hours are required to detect potential delayed cardiotoxicity and CNS depression.

Population Considerations

Pediatric patients (especially those under 2 years) are at a greater risk for severe respiratory and cardiac events, while patients with hepatic impairment require close monitoring for signs of CNS toxicity.

Therapeutic Uses of Undiarrhea

Undiarrhea: Main Uses and Therapeutic Benefits

Undiarrhea is indicated for the symptomatic control of diarrhea. Its primary application is in managing both acute nonspecific diarrhea and chronic diarrhea associated with conditions like inflammatory bowel disease (IBD).

The medication's benefit comes from its effect on the gastrointestinal system. It helps to reduce intestinal motility and decrease the frequency of bowel movements. By slowing down the movement of the gut, Undiarrhea allows for increased absorption of fluid and electrolytes, which are often lost during diarrhea, thereby improving stool consistency.

Specific uses approved by health authorities include the treatment of Traveler's Diarrhea and reducing the volume of discharge from an ileostomy. Patients should consult a healthcare professional if symptoms of acute diarrhea persist for more than 48 hours.


Quick Facts: Undiarrhea's Therapeutic Domain

  • Acute Diarrhea: Manages sudden, short-term loose stools.
  • Chronic Diarrhea: Used for persistent loose stools, often related to conditions like IBD.
  • Traveler's Diarrhea: Provides symptomatic relief during travel-related episodes.
  • Ileostomy Discharge: Helps to reduce the volume of fluid discharge.

Eligibility and Restrictions for Use

The active ingredient in Undiarrhea, loperamide, is indicated for the control and symptomatic relief of acute, nonspecific diarrhea in adults and children aged 6 years and older. In some formulations, it is also used for chronic diarrhea associated with Inflammatory Bowel Disease (IBD) and to reduce ileostomy discharge.


Contraindications

Undiarrhea should not be used in the following situations or patient groups:

  • Children under 2 years of age due to the risk of serious breathing and heart problems.
  • Individuals with a known allergy to loperamide or any other product ingredients.
  • Patients with abdominal pain in the absence of diarrhea.
  • Patients experiencing acute dysentery (diarrhea with bloody stools and high fever).
  • Diarrhea associated with specific bacterial enterocolitis or pseudomembranous colitis (e.g., severe diarrhea after antibiotic use).
  • Patients with conditions where inhibition of intestinal movement must be avoided, such as signs of constipation, abdominal distension, or ileus.

Use with caution and only under a healthcare professional's guidance in patients with liver disease, advanced HIV/AIDS, or a history of heart rhythm problems, as loperamide may pose increased risks in these populations.

What should I know about interactions with other medicines?

The interaction profile for Undiarrhea is structured by its status as a substrate for both metabolic enzymes and a cellular transporter. Pharmacokinetic interactions are documented with agents that inhibit its clearance, leading to a significant increase in its plasma concentration. This includes strong inhibitors of the CYP3A4 and CYP2C8 metabolic enzymes, such as Itraconazole and Gemfibrozil. Similarly, co-administration with P-glycoprotein (P-gp) efflux transporter inhibitors like Quinidine and Ritonavir is officially noted to cause up to a three-fold increase in exposure. Combinations of these inhibitors are documented to cause even larger increases, reaching up to 13-fold. Conversely, Undiarrhea may decrease the exposure of other co-administered P-gp substrates, such as Saquinavir.

A critical pharmacodynamic interaction constraint is the formally established risk with medicines that prolong the QT interval. Co-administration with these high-risk substances, including examples such as Pimozide and Thioridazine, creates an additive risk for serious ventricular arrhythmias and is officially classified as a combination to be avoided. Caution is also noted for co-administration with other agents that inhibit intestinal motility. Furthermore, the systemic exposure resulting from these pharmacokinetic interactions may be clinically amplified in patients with hepatic impairment due to reduced clearance. Concomitant use with alcohol may reinforce central nervous system effects such as drowsiness.

Mechanism of Action

The mechanism of action for Loperamide hydrochloride, the active ingredient in Undiarrhea, is defined by its highly selective activity on the regulatory systems within the gastrointestinal tract.

Peripheral mu-Opioid Receptor Engagement

Loperamide functions as an agonist that selectively binds to peripheral mu-opioid receptors (MOR) located on the neurons of the enteric nervous system in the gut wall. This peripheral selectivity, aided by the P-glycoprotein transporter, results in the drug's action remaining primarily localized to the gastrointestinal tract, limiting its interaction with the central nervous system.

Modulation of Enteric Neurotransmission and Motility

The activation of peripheral mu-opioid receptors initiates an inhibitory signaling cascade that suppresses the presynaptic release of excitatory neurotransmitters, primarily Acetylcholine and Prostaglandins. This reduction in chemical signaling directly inhibits the coordinated propulsive peristaltic contractions of the smooth muscle, leading to an increase in intestinal transit time.

Enhancement of Fluid Reabsorption and Homeostasis

The resulting delay in the movement of contents through the intestines extends the time available for the gut wall to perform its primary function: the reabsorption of water and electrolytes. This physiological adjustment, combined with an indirect anti-secretory component, promotes the retention of fluid and electrolytes within the circulation.

Dosage and Administration Information

Official Labeled Instructions for Use

This section outlines the proper administration of loperamide (the active ingredient in Undiarrhea).

1. Administration Route and Form

Loperamide is strictly administered by the oral route (by mouth). It is available as capsules (2 mg), tablets (2 mg), and oral solution/suspension (liquid form). If using the liquid, the bottle should be shaken well before use, and a calibrated measuring device must be used to ensure the correct dose is administered.

2. Dosing Schedule and Limits

The standard dosing regimen is an event-contingent schedule. The initial dose is administered once, followed by a subsequent dose after each unformed stool. Doses must not exceed the specified daily limits:

Population Initial Dose Subsequent Dose (After Each Unformed Stool) Maximum Daily Dose (OTC)
Adults 4 mg 2 mg 8 mg
Children 9-11 yrs 2 mg 2 mg 6 mg

3. Course Duration and Restrictions

For self-treatment of acute diarrhea, Loperamide should not be used for more than 48 hours (2 days) unless directed by a healthcare professional. Dosing must not exceed the maximum limits stated in the labeling. It is contraindicated and must not be used in children under 2 years of age.

Recent Clinical Evidence

Research Evidence for Acute Short-Term Diarrhea

Research was studied for this use primarily in Randomized Controlled Trials (RCTs). These studies explored how symptoms change over time in acute episodes, such as non-specific and traveler’s diarrhea. Researchers focused on objective outcomes like the time required for the final measured unformed stool and changes in stool frequency over brief periods.

Studies reported measurements related to the time measured to the last unformed stool. The available evidence is focused on short-term symptomatic measurement and provides limited insight into the use of the compound in patients with more severe illness.


Studies Examining Chronic Diarrhea and Bowel Conditions

The compound was evaluated for conditions characterized by fluctuating manifestations, such as persistent diarrhea linked to Inflammatory Bowel Disease (IBD). The evidence base includes Controlled Clinical Trials and Observational Studies. These studies examined outcomes related to systemic or functional imbalance (stool frequency and weight) and patient-reported changes in consistency.

Research describes patterns that included variability across severities. Sample sizes were modest in several controlled trials, and the available evidence varies in quality across studies.


Evidence on Surgical and Specialty Use (Ileostomy)

Specific controlled studies were conducted on Adults with an ileostomy. The research primarily examined objective measurements of ileostomy output (volume or weight). The research focus is highly centered on these short-term physiological measurements. The controlled research relies on sample sizes that were modest, and follow-up durations were limited, concentrating on immediate effect rather than long-term effects.


Studies in Specific Patient Groups (Populations)

Studies have explored the compound across different age groups, including Children (older than 2 or 3 years of age) and Older Adults. Results apply only to the populations studied, meaning the patterns observed in the general adult population may not perfectly reflect outcomes in more specific groups. Data for certain groups remain insufficient.


Durability of Effect and Extended Follow-up

Most evidence was observed in research exploring short-term symptom changes over a few days or weeks. Follow-up durations were limited across acute care trials. Long-term effects are not fully established beyond the specific timeframes of the clinical trials.


Gaps in Research and Areas of Uncertainty

Scientific understanding is continually evolving, and certain areas of research remain insufficient. One key limitation is that sample sizes were modest. Data for certain groups remain insufficient, such as patients who have severe illness. The available evidence, which includes different study designs, varies in quality across studies.

Key Studies & References

  1. Clinical evaluation of loperamide: a potent, peripherally acting, antidiarrheal agent

Frequently Asked Questions (FAQ)

Common questions about Undiarrhea (FAQ)

Q: How quickly can a person expect to feel the effects of Undiarrhea?

A: Regulatory information suggests that the time it takes for the drug to reach its maximum concentration (peak effect) in the body can vary depending on the specific dosage form used, such as a solution versus a capsule. While some effects may be observed sooner, the maximum effect often occurs several hours after the medicine is taken.


Q: Can Undiarrhea cause drowsiness or affect driving ability?

A: Official documents state that the medicine may cause side effects like dizziness or drowsiness. Therefore, official documents contain warnings and caution is noted regarding driving or operating machinery.


Q: Can Undiarrhea be used by patients with kidney function issues?

A: According to safety restrictions outlined in regulatory documents, patients with moderate to severe renal (kidney) impairment require a dosage adjustment. Regulatory documents note that usage in this population may require individual adjustment, which is typically managed by a healthcare professional.


Q: If I am taking vitamins or supplements, can I still take Undiarrhea?

A: Official patient guidance recommends informing a healthcare professional about all medicines, including over-the-counter supplements and vitamins. This disclosure is important because some supplements and vitamins may not be compatible with the drug.


Q: What are the main findings from the most recent research on Undiarrhea?

A: Research studies and clinical trials generally focus on objective measurements of how quickly symptoms change or improve. These outcomes are often tracked using endpoints like the time required for the last unformed stool or by measuring changes in symptoms using specific gastrointestinal rating scales.


Q: If I miss a dose of Undiarrhea, what generally happens?

A: For scheduled dosing regimens, official guidance often suggests taking the missed dose upon remembering. If it is close to the time of the next scheduled dose, the missed dose is typically skipped, and a regular schedule is followed. Taking double doses is not recommended.


Q: Are there any specific foods or drinks that should be avoided when taking Undiarrhea?

A: Official patient documents emphasize the importance of drinking plenty of clear fluids to replace those lost due to diarrhea. Specific foods or drinks are generally not listed as direct contraindications or interaction risks in the official product information.


Q: Why is Undiarrhea available over-the-counter in some countries but requires a prescription in others?

A: The legal status of a drug, whether it is non-prescription or requires a prescription, is determined by the specific regulatory body in each country. These decisions reflect local restrictions, historical safety reviews, and the permitted maximum dosages for self-treatment.


Q: What are some of the most commonly reported temporary side effects of Undiarrhea?

A: Based on documented frequency data provided by regulatory agencies, the most commonly reported temporary side effects include headache and dry mouth. Other frequently reported effects are nausea, dizziness, and abdominal pain.


Q: Is it true that Undiarrhea can interact with blood thinners?

A: The official drug interaction profile primarily cites interactions with specific enzyme inhibitors, such as those affecting CYP and P-gp pathways. Authoritative sources note that caution is required when using the drug alongside other medicines that may affect similar metabolic pathways.


Q: Can Undiarrhea be taken by someone who is fasting?

A: According to patient information leaflets, the drug is authorized to be taken either with or without food.


Q: Why do some people say Undiarrhea stops working for them after a while?

A: According to official regulatory data and pharmacological studies, tolerance to the antidiarrheal effect of the active ingredient has not been formally documented.


Q: What should a person do if they accidentally take more Undiarrhea than intended?

A: Official safety warnings emphasize that taking more than the recommended amount is associated with an increased risk of serious cardiac events. These warnings highlight the potential for serious cardiac events, including heart rhythm changes, when taking amounts beyond the recommended dosage.


Q: Is there a generic version of Undiarrhea available?

A: Yes, the active ingredient in Undiarrhea, loperamide, is widely available as a generic medication across many international markets.


Q: Is the active ingredient in Undiarrhea commonly used in other medicines?

A: The active ingredient is a commonly used and globally recognized compound. It is frequently formulated into various medicines for the symptomatic control of acute and chronic diarrhea.


Q: Why is the drug Undiarrhea sometimes associated with heart-related concerns?

A: Regulatory documents warn that use outside of the approved indication or at extremely high doses is associated with the risk of serious cardiac rhythm issues.


Q: Does the time of day affect how Undiarrhea works?

A: The dosing schedule for the over-the-counter use of this medicine is typically event-contingent, meaning it is taken after an unformed stool. Therefore, the drug’s efficacy is not tied to a specific time of day.


Q: Is it normal to feel slightly bloated after starting Undiarrhea?

A: Bloating and general abdominal discomfort are listed in regulatory sources as possible rare side effects. It is described in official documents that the presence of significant abdominal distension or severe abdominal pain is a listed reason to avoid or discontinue use.


Q: Do regulatory agencies list any potential dependence or withdrawal issues with Undiarrhea?

A: Cases of drug withdrawal syndrome have been observed following abrupt discontinuation, but only in individuals who have intentionally taken extremely high doses of the drug (abuse or misuse) for unapproved indications.


Q: Does Undiarrhea help replenish lost electrolytes?

A: Official documents clearly emphasize that while the medicine works to retain fluids, its use does not replace the need for appropriate fluid and electrolyte replacement therapy. This replacement must be administered as needed, especially during severe dehydration.


Q: Does Undiarrhea change the color or consistency of stools?

A: The drug's mechanism of action is designed to slow intestinal movement, allowing for greater water absorption, which results in firmer stools. The medicine is not officially documented to change the color of stools.


Q: Why is Undiarrhea sometimes mentioned in discussions about irritable bowel syndrome (IBS)?

A: Official documents indicate that the active ingredient is approved in certain formulations for the symptomatic treatment of diarrhea associated with medically diagnosed Irritable Bowel Syndrome (IBS) in adults.


Q: What effect does Undiarrhea have on the gut flora or 'good' bacteria?

A: Research has observed that changes in the gut microbiota are a consequence of the medicine increasing intestinal transit time. It is not generally described as a direct interaction between the active ingredient and the gut flora.


Q: Are there any specific legal age restrictions for purchasing Undiarrhea?

A: Legal purchase restrictions for the medicine vary by country and formulation. Restrictions sometimes limit the sale of certain package sizes or require the patient to meet specific age criteria, such as being 18 years or older for certain uses.


Q: What happens if Undiarrhea is taken without food?

A: The medicine is authorized to be taken either with or without food, according to patient information leaflets.


Q: Are there different strengths or formulations of Undiarrhea available?

A: Yes, the medicine is available in several different dosage forms, including capsules, tablets, and oral solution/suspension. For single-entity products, the dosage is typically standardized to a 2 mg strength.


Q: Are there specific symptoms that indicate Undiarrhea should be stopped?

A: Official patient information lists specific severe symptoms, such as rash, swelling, difficulty breathing, or severe abdominal symptoms, as conditions under which the medication should be discontinued.


Q: Do any official drug documents list anxiety as a potential side effect of Undiarrhea?

A: Anxiety is not listed as an adverse reaction in the frequency-classified side effect data provided in authoritative regulatory documents.


Q: How do the clinical trials for Undiarrhea define 'improvement'?

A: Clinical trials typically define improvement using objective outcomes, such as the time measured to the last unformed stool or by observing changes in stool frequency and consistency.


Q: What is the general recommended length of time someone should use Undiarrhea?

A: The medicine is officially intended for short-term use. For the self-treatment of acute diarrhea, regulatory guidelines indicate that the duration of use is not to exceed 48 hours (2 days).

How should Undiarrhea be stored and disposed of?

Storage and Disposal Requirements for Loperamide (Undiarrhea)

The medicine's storage must strictly follow regulatory guidance to maintain stability and prevent accidental harm. Oral solid forms, such as capsules, typically require storage below 30 C. Liquid formulations often require storage between 20 C and 25 C (68 F and 77 F) and must not be frozen.

Required Precautions

All loperamide products must be stored in their original unit-dose packaging and out of the sight and reach of children, as required by mandated safety labeling. The labeled shelf life is conditional on adherence to these storage constraints.

Disposal

Expired or unused medicine must be disposed of according to local regulations and the specific guidelines provided by national health authorities, avoiding disposal through general household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Undiarrhea found in:

A-Z Index: